First Full Year of Profitability with GAAP Earnings Per Share of $0.03
2008 Nexavar Net Sales of $678 Million Represents 82% Growth Over 2007
EMERYVILLE, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the full year and fourth quarter 2008. For the full year, Onyx recorded net income of $1.9 million, or $0.03 per diluted share, compared with a net loss of $34.2 million, or $0.67 per diluted share, for the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the full year 2008 was $20.7 million, or $0.37 per diluted share, compared to a non-GAAP net loss of $20.0 million, or $0.39 per diluted share, for the same period in 2007. Onyx reported a net loss of $30.2 million, or $0.53 per diluted share, for the fourth quarter 2008, compared to a net loss of $11.7 million, or $0.21 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net loss for the fourth quarter 2008 was $25.2 million, or $0.45 per diluted share, compared to a non-GAAP net loss of $7.8 million, or $0.14 per diluted share, for the same period in 2007. A description of the non-GAAP calculations and reconciliation to comparable GAAP measures are provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.
Global Nexavar net sales grew 82% to $677.8 million for the full year 2008, and grew 41% to $176.5 million for the fourth quarter 2008, compared to $371.7 million and $124.9 million in the same periods in 2007. Onyx, with its collaborator, Bayer HealthCare Pharmaceuticals, Inc., or Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in th
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved